Close Menu


Myriad and Cepheid discussed their pipelines, while Exact Sciences provided some details of its upcoming trial on its colon cancer test, and Danaher touted its success with past acquisitions as it nears closing of its Beckman Coulter buy.

Complete Genomics CEO Clifford Reid outlined goals for his firm, while Affymetrix CFO Tim Barabe spoke about market opportunities and a shift in the firm's business model.

Jefferies also increased the firm's stock price target to $20 from $15.50.

The Jefferies analyst also elevated the target share price for Agilent on expectations of healthy organic revenues and "immaterial" effects from the Japanese earthquake and tsunami on Agilent's business.

Jefferies analyst Jon Wood also raised his price target on the firm's stock to $15.50 from $13, following a presentation by Complete Genomics CEO Clifford Reid at a biotech conference.


The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.